Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Overview Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Companies Involved in Therapeutics Development Gila Therapeutics Inc Novo Nordisk A/S XL-protein GmbH Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Drug Profiles Gene Therapy to Activate Neuropeptide Y Receptor Y2 and Y5 for Epilepsy - Drug Profile Product Description Mechanism Of Action R&D Progress GT-001 - Drug Profile Product Description Mechanism Of Action R&D Progress GT-002 - Drug Profile Product Description Mechanism Of Action R&D Progress NN-9748 - Drug Profile Product Description Mechanism Of Action R&D Progress XL-310 - Drug Profile Product Description Mechanism Of Action R&D Progress Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Dormant Products Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Product Development Milestones Featured News & Press Releases Nov 09, 2012: Novel treatment strategies for epilepsy Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indication, H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pipeline by Gila Therapeutics Inc, H1 2017 Pipeline by Novo Nordisk A/S, H1 2017 Pipeline by XL-protein GmbH, H1 2017 Dormant Projects, H1 2017 List of Figures Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indications, H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Molecule Types, H1 2017 Number of Products by Stage and Molecule Types, H1 2017

Gila Therapeutics Inc Novo Nordisk A/S XL-protein GmbH